- Home
- CCHH vs HURA Comparison
CCHH vs HURA Comparison
Compare CCHH & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCHH
- HURA
- Stock Information
- Founded
- CCHH 2015
- HURA 2009
- Country
- CCHH Malaysia
- HURA United States
- Employees
- CCHH N/A
- HURA N/A
- Industry
- CCHH
- HURA
- Sector
- CCHH
- HURA
- Exchange
- CCHH Nasdaq
- HURA Nasdaq
- Market Cap
- CCHH 113.0M
- HURA 131.8M
- IPO Year
- CCHH 2025
- HURA N/A
- Fundamental
- Price
- CCHH $5.84
- HURA $1.98
- Analyst Decision
- CCHH
- HURA Strong Buy
- Analyst Count
- CCHH 0
- HURA 2
- Target Price
- CCHH N/A
- HURA $11.50
- AVG Volume (30 Days)
- CCHH 321.3K
- HURA 182.6K
- Earning Date
- CCHH 11-28-2025
- HURA 11-14-2025
- Dividend Yield
- CCHH N/A
- HURA N/A
- EPS Growth
- CCHH N/A
- HURA N/A
- EPS
- CCHH 0.03
- HURA N/A
- Revenue
- CCHH $8,915,344.00
- HURA N/A
- Revenue This Year
- CCHH N/A
- HURA N/A
- Revenue Next Year
- CCHH N/A
- HURA N/A
- P/E Ratio
- CCHH $192.80
- HURA N/A
- Revenue Growth
- CCHH N/A
- HURA N/A
- 52 Week Low
- CCHH $3.49
- HURA $1.80
- 52 Week High
- CCHH $8.25
- HURA $7.20
- Technical
- Relative Strength Index (RSI)
- CCHH N/A
- HURA 28.73
- Support Level
- CCHH N/A
- HURA $2.01
- Resistance Level
- CCHH N/A
- HURA $2.60
- Average True Range (ATR)
- CCHH 0.00
- HURA 0.15
- MACD
- CCHH 0.00
- HURA -0.05
- Stochastic Oscillator
- CCHH 0.00
- HURA 1.47
About CCHH CCH Holdings Ltd Ordinary Shares
CCH Holdings Ltd operates a hotpot restaurant chain in Malaysia, specializing in chicken hotpot and fish head hotpot, mainly under two brand, namely Chicken Claypot House and Zi Wei Yuan, owned by the wholly owned subsidiaries of the Company. The Company conducts its operations through its wholly owned subsidiaries in Malaysia and is engaged as a restaurant operator, licensor and loyalty owner, and general trader. Currently, the Group has developed a restaurant chain including approximately 15 company-owned restaurant outlets, 13 franchised restaurant outlets in Malaysia, and 4 franchised restaurant outlets outside Malaysia.
About HURA TuHURA Biosciences Inc. Common Stock
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.